Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.15B | — | $1.77B | $1.83B | $1.86B | $2.23B | $2.54B | $2.74B | $3.11B | $3.31B |
| Revenue growth | — | — | — | 3.4% | 1.6% | 19.6% | 14.1% | 8.0% | 13.5% | 6.2% |
| Operating income | $196M | — | $77.8M | $236M | $183M | $302M | $345M | $328M | $349M | $390M |
| Operating margin | 17.2% | — | 4.4% | 12.9% | 9.8% | 13.6% | 13.6% | 12.0% | 11.2% | 11.8% |
| Net income | $9.45M | — | -$206M | -$74.8M | -$116M | -$70.9M | -$54.6M | -$11.9M | -$168M | -$77.9M |
| Net margin | 0.8% | — | -11.6% | -4.1% | -6.2% | -3.2% | -2.2% | -0.4% | -5.4% | -2.4% |
| EPS (diluted) | $0.20 | — | -$4.96 | -$2.29 | -$3.19 | -$1.12 | -$0.59 | -$0.09 | -$1.33 | -$0.61 |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $125M | — | $145M | $130M | $247M | $87.1M | $159M | $294M | $300M | $274M |
| Capital expenditures | $39.1M | — | $39.8M | $73.6M | $42.9M | $57.6M | $80.6M | $88.8M | $90.4M | $78.7M |
| Free cash flow | $86.1M | — | $105M | $55.9M | $204M | $29.5M | $78.2M | $205M | $210M | $196M |
| Share buybacks | $0.00 | — | $2.00M | $0.00 | $0.00 | — | — | — | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $69.7M | $175M | $184M | $92.7M | $318M | $390M | $283M | $196M | $270M | $240M |
| Total assets | $2.30B | $4.62B | $4.68B | $5.02B | $5.41B | $6.12B | $6.68B | $6.88B | $7.89B | $8.12B |
| Long-term debt | $1.47B | $2.19B | $2.33B | $2.60B | $2.88B | $2.96B | $2.63B | $2.80B | $3.40B | $3.74B |
| Shareholders' equity | $9.68M | $655M | $405M | $297M | $116M | $1.09B | $2.00B | $1.99B | $1.79B | $1.71B |
| Retained earnings | -$311M | -$41.3M | -$247M | -$316M | -$432M | -$503M | -$557M | -$569M | -$737M | -$815M |
| Shares (wtd avg diluted) | 48.2M | 48.7M | 48.0M | 48.3M | 48.8M | 72.4M | 92.0M | 126M | 126M | 127M |
Every figure is extracted from Surgery Partners, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.